A Phase 1 Dose-Escalation Study of Oral ARRY-438162 in Patients With Advanced Solid Tumors Followed by an Expansion Cohort in Patients With Advanced or Metastatic Biliary Cancer

Trial Profile

A Phase 1 Dose-Escalation Study of Oral ARRY-438162 in Patients With Advanced Solid Tumors Followed by an Expansion Cohort in Patients With Advanced or Metastatic Biliary Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2018

At a glance

  • Drugs Binimetinib (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Array BioPharma
  • Most Recent Events

    • 22 May 2018 Results (n=28) assessing the tolerability, pharmacokinetics, and pharmacodynamics of ARRY 162 in patients with advanced solid tumours, followed by expansion cohorts in patients with advanced or metastatic biliary cancer and in patients with KRAS-mutant and BRAF-mutant colorectal cancer, were published in the Investigational New Drugs.
    • 02 Feb 2017 Results published in the British Journal of Cancer
    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top